Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial
- 26 August 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (8) , 921-924
- https://doi.org/10.1161/01.cir.0000088780.57432.43
Abstract
Background— Statins primarily metabolized by cytochrome P450 3A4 (CYP3A4) reportedly reduce clopidogrel’s metabolism to active metabolite, thus attenuating its inhibition of platelet aggregation ex vivo. However, the clinical impact of this interaction has not been evaluated.Keywords
This publication has 6 references indexed in Scilit:
- The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by AtorvastatinDrug Metabolism and Disposition, 2003
- Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary InterventionJAMA, 2002
- Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrelPlatelets, 2001
- In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin*Clinical Pharmacology & Therapeutics, 1995
- The Antiaggregating Activity of Clopidogrel Is due to a Metabolic Activation by the Hepatic Cytochrome P450-1AThrombosis and Haemostasis, 1994